Integrated functional genomic screening to bypass TKI resistance in chronic myeloid leukemia.
basic_science · Level V
Where this comes from
- Record sourced from PubMed, PMID 38776875.
- Also identified by DOI 10.1016/j.xcrm.2024.101565 and PMC identifier 11148797.
- Licence recorded as CC BY.
- The licence permits redistribution, so the abstract is shown in full and the full text is available from the publisher.
Abstract
CML is readily treatable with tyrosine kinase inhibitors (TKIs); however, resistance occurs, with the disease curable in only ∼15%-20% of patients. Using integrated functional genomics, Adnan Awad et al.<sup>1</sup> identify agents effective against CML stem cells and describe mechanisms underlying TKI resistance.
Medical subject headings
- Leukemia, Myelogenous, Chronic, BCR-ABL Positive
- Protein Kinase Inhibitors
- Drug Resistance, Neoplasm
- Genomics